As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.
17 Analysts have issued a Arcturus Therapeutics Ltd forecast:
17 Analysts have issued a Arcturus Therapeutics Ltd forecast:
| Sep '25 |
+/-
%
|
||
| Revenue | 98 98 |
39%
39%
|
|
| Gross Profit | - - |
-
|
|
| EBITDA | -75 -75 |
2%
2%
|
|
| EBIT (Operating Income) EBIT | -78 -78 |
3%
3%
|
|
| Net Profit | -67 -67 |
6%
6%
|
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Arcturus Therapeutics Holdings, Inc. engages in the research and development of medical applications for the nucleic acid-focused technology. The firm develops RNA therapeutics which focuses on the treatment of liver and respiratory diseases. Its pipeline include LUNAR-OTC and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.
| Head office | Israel |
| CEO | Joseph Payne |
| Employees | 175 |
| Founded | 2013 |
| Website | arcturusrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.


